Evidence map›Paper›PMID 38335304›Full record

ArticleCancer research2024

Single-Cell Analysis Identifies NOTCH3-Mediated Interactions between Stromal Cells That Promote Microenvironment Remodeling and Invasion in Lung Adenocarcinoma.

Handan Xiang, Yidan Pan, Marc A Sze, Marta Wlodarska, Ling Li, Karyn Ann van de Mark, Haleema Qamar, Casey J Moure, Douglas E Linn, Josephine Hai and 19 more

Open access · hybridAbstract read
In one paragraph

Article in Cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 2 pooled it
10.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 4 institutions in 2 countries.

Handan Xiang *Discovery Immunology, Merck & Co., Inc., Cambridge, Massachusetts.ORCID 0000-0001-7957-7336
Yidan Pan *Data and Genome Sciences, Merck & Co., Inc., Boston, Massachusetts.ORCID 0000-0002-9702-8530
Marc A SzeData and Genome Sciences, Merck & Co., Inc., Boston, Massachusetts.ORCID 0000-0002-3532-9653
Marta WlodarskaDiscovery Oncology, Merck & Co., Inc., Boston, Massachusetts.ORCID 0009-0002-1331-0721
Ling LiQuantitative Bioscience, MSD, Singapore.ORCID 0009-0005-3287-5797
Karyn Ann van de MarkDiscovery Immunology, Merck & Co., Inc., Cambridge, Massachusetts.ORCID 0009-0003-0475-0255
Haleema QamarDiscovery Immunology, Merck & Co., Inc., Cambridge, Massachusetts.ORCID 0000-0003-1599-4020
Casey J MoureDiscovery Oncology, Merck & Co., Inc., Boston, Massachusetts.ORCID 0000-0001-5094-2213
Douglas E LinnQuantitative Bioscience, Merck & Co., Inc., Boston, Massachusetts.ORCID 0009-0000-4500-5284
Josephine HaiQuantitative Bioscience, Merck & Co., Inc., Boston, Massachusetts.ORCID 0000-0002-5842-7686
Ying HuoQuantitative Bioscience, Merck & Co., Inc., Boston, Massachusetts.ORCID 0009-0009-6007-5550
James ClarkeData and Genome Sciences, Merck & Co., Inc., Boston, Massachusetts.ORCID 0009-0001-8803-4728
Tze Guan TanDiscovery Cardiometabolic Diseases, MSD, Singapore.ORCID 0000-0002-3777-2640
Samantha HoDiscovery Cardiometabolic Diseases, MSD, Singapore.ORCID 0009-0007-0931-4080
Karen W TengDiscovery Cardiometabolic Diseases, MSD, Singapore.ORCID 0009-0008-7845-1959
Muhammad N RamliQuantitative Bioscience, MSD, Singapore.ORCID 0009-0000-1325-2555
Michael NebozhynData and Genome Sciences, Merck & Co., Inc., Boston, Massachusetts.ORCID 0000-0001-8835-7714
Chunsheng ZhangData and Genome Sciences, Merck & Co., Inc., Boston, Massachusetts.ORCID 0009-0003-7225-6056
Julianne BarlowThe Division of Thoracic Surgery, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0009-0008-3443-4276
Corinne E GustafsonThe Division of Thoracic Surgery, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-9468-3388
Savanna GornisiewiczThe Division of Thoracic Surgery, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-1113-7868
Thomas P AlbertsonThe Division of Thoracic Surgery, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-5477-7566
Stephanie L KorleThe Division of Thoracic Surgery, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0009-0001-7110-921X
Raphael BuenoThe Division of Thoracic Surgery, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-3231-5491
Lily Y MoyQuantitative Bioscience, Merck & Co., Inc., Boston, Massachusetts.ORCID 0000-0003-2999-2093
Elisabeth H VollmannDiscovery Immunology, Merck & Co., Inc., Cambridge, Massachusetts.ORCID 0000-0002-8569-515X
Derek Y ChiangData and Genome Sciences, Merck & Co., Inc., Boston, Massachusetts.ORCID 0000-0002-1131-6065
Philip E BrandishDiscovery Oncology, Merck & Co., Inc., Boston, Massachusetts.ORCID 0000-0002-5591-8973
Andrey LobodaData and Genome Sciences, Merck & Co., Inc., Boston, Massachusetts.ORCID 0000-0003-4239-184X
Merck & Co., Inc., Rahway, NJ, USA (United States) · USBrigham and Women's Hospital · USDxDiscovery (United States) · USWaseda Bioscience Research Institute in Singapore · SG

Funding

Merck & Co. Inc., Research Laboratories Postdoc ProgramMerck & Co., Inc., Research Laboratories Postdoc Program
6 · The paper itself

Abstract

Cancer immunotherapy has revolutionized the treatment of lung adenocarcinoma (LUAD); however, a significant proportion of patients do not respond. Recent transcriptomic studies to understand determinants of immunotherapy response have pinpointed stromal-mediated resistance mechanisms. To gain a better understanding of stromal biology at the cellular and molecular level in LUAD, we performed single-cell RNA sequencing of 256,379 cells, including 13,857 mesenchymal cells, from 9 treatment-naïve patients. Among the mesenchymal cell subsets, FAP+PDPN+ cancer-associated fibroblasts (CAF) and ACTA2+MCAM+ pericytes were enriched in tumors and differentiated from lung-resident fibroblasts. Imaging mass cytometry revealed that both subsets were topographically adjacent to the perivascular niche and had close spatial interactions with endothelial cells (EC). Modeling of ligand and receptor interactomes between mesenchymal and ECs identified that NOTCH signaling drives these cell-to-cell interactions in tumors, with pericytes and CAFs as the signal receivers and arterial and PLVAPhigh immature neovascular ECs as the signal senders. Either pharmacologically blocking NOTCH signaling or genetically depleting NOTCH3 levels in mesenchymal cells significantly reduced collagen production and suppressed cell invasion. Bulk RNA sequencing data demonstrated that NOTCH3 expression correlated with poor survival in stroma-rich patients and that a T cell-inflamed gene signature only predicted survival in patients with low NOTCH3. Collectively, this study provides valuable insights into the role of NOTCH3 in regulating tumor stroma biology, warranting further studies to elucidate the clinical implications of targeting NOTCH3 signaling. SIGNIFICANCE: NOTCH3 signaling activates tumor-associated mesenchymal cells, increases collagen production, and augments cell invasion in lung adenocarcinoma, suggesting its critical role in remodeling tumor stroma.

Indexed as

Adenocarcinoma of LungCancer-Associated FibroblastsLung NeoplasmsNeoplasm InvasivenessReceptor, Notch3Single-Cell AnalysisStromal CellsTumor MicroenvironmentCell CommunicationHumansSignal TransductionNOTCH3 protein, humanReceptor, Notch3

Identifiers

PMID38335304
PMCPMC11063690
OpenAlexW4391677297

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.